Abstract:While it is now accepted that the gut microbiota contribute to the genotype-environment-lifestyle interactions triggering inflammatory bowel disease (IBD) episodes, efforts to identify the pathogen(s) that cause these diseases have met with limited success. The advent of culture-independent techniques for characterizing the structure and/or function of microbial communities (hereafter referred to as metagenomics) has provided new insights into the events associated with the onset, remission and recurrence of IBD. A large number of observational and/or case-control studies of IBD patients have confirmed substantive changes in gut bacterial profiles (dysbiosis) associated with disease. These types of studies have been augmented by new profiling approaches that support the identification of more ‘colitogenic' bacteria from numerically predominant taxa. Evidence of alterations in lesser abundant taxa such as the methanogenic archaea, to favor types that are more immunogenic, has also been forthcoming. Several recent longitudinal studies of patients with Crohn's disease have produced additional insights, including evidence for the role of ‘anti-inflammatory' microbiota in providing a protective effect and/or promoting remission. In summation, the implications of dysbiosis and restoration of a ‘healthy microbiota' in IBD patients requires definition beyond a taxonomic assessment of the changes in the gut microbiota during disease course. The available evidence does suggest that specific members of the gut microbiota can contribute either pro- or anti-inflammatory effects, and their ecological fitness in the large bowel affects the onset and recurrence of IBD. While metagenomics and related approaches offer the potential to provide novel and important insights into these microbiota and thereby the pathophysiology of IBD, we also need to better understand factors affecting the ecological fitness of these microbes, if new treatment of IBD patients are to be delivered.

Specific changes of enteric mycobiota and virome in inflammatory bowel disease

Roles of Gut Bacteriophages in the Pathogenesis and Treatment of Inflammatory Bowel Disease

Review article: fungal alterations in inflammatory bowel diseases

The gut ileal mucosal virome is disturbed in patients with Crohn’s disease and exacerbates intestinal inflammation in mice

Gut microbiota and inflammatory bowel disease: The current status and perspectives

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Updated immunomodulatory roles of gut flora and microRNAs in inflammatory bowel diseases

The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy

Dynamic impact of virome on colitis and colorectal cancer: Immunity, inflammation, prevention and treatment

The microbiome in inflammatory bowel diseases: from pathogenesis to therapy

Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease

Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection

New Insights into the Role of Oral Microbiota Dysbiosis in the Pathogenesis of Inflammatory Bowel Disease

Interactions between Intestinal Microbiota and Host Immune Response in Inflammatory Bowel Disease.

Recent progress on engineered micro/nanomaterials mediated modulation of gut microbiota for treating inflammatory bowel disease

Dietary Patterns and Gut Microbiota Changes in Inflammatory Bowel Disease: Current Insights and Future Challenges

Gut virome in inflammatory bowel disease and beyond

The emerging role of the gut microbiota and its application in inflammatory bowel disease

Unveiling the overlooked fungi: the vital of gut fungi in inflammatory bowel disease and colorectal cancer

Effect of diet on the gut mycobiome and potential implications in inflammatory bowel disease

Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives